Antibodies
4 September 2024
OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors4 September 2024
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema4 September 2024
Degrader-Antibody Conjugates: an emerging novel drug modality with the best of ADCs and targeted protein degraders3 September 2024
IgGenix Presents Data Supporting Clinical Development of IGNX001 for Peanut Allergy at the 2024 ASCIA Annual Conference30 August 2024
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis29 August 2024
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan28 August 2024
Cantargia reports timelines for nadunolimab clinical trials in leukemia and triple negative breast cancer27 August 2024
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH27 August 2024
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology22 August 2024
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports